|
|
Volumn 97, Issue 24, 2005, Pages 1802-1804
|
|
Accelerated approval regulations may need overhaul, panel suggests
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
ANTINEOPLASTIC AGENT;
ANTIRETROVIRUS AGENT;
CELECOXIB;
CYTARABINE;
DENILEUKIN DIFTITOX;
DOXORUBICIN;
GEMTUZUMAB OZOGAMICIN;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ACUTE GRANULOCYTIC LEUKEMIA;
ADENOMATOUS POLYP;
CANCER;
CANCER CHEMOTHERAPY;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG INDICATION;
DRUG MARKETING;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
KAPOSI SARCOMA;
MENINGITIS;
NOTE;
PRIORITY JOURNAL;
T CELL LYMPHOMA;
ANTIBIOTICS, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DOXORUBICIN;
DRUG APPROVAL;
DRUGS, INVESTIGATIONAL;
HUMANS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 29844435926
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/dji456 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|